TLSI NASDAQ
TriSalus Life Sciences, Inc.
1W: -30.9%
1M: -31.5%
3M: -32.1%
YTD: -48.4%
1Y: -38.7%
3Y: -69.7%
5Y: -67.4%
$3.15
+0.12 (+3.96%)
Weekly Expected Move ±21.6%
$2
$2
$3
$3
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$3.6M
Congress—
ETF Holdings—
Key Statistics
Market Cap$119.4M
52W Range2.2-7.95
Volume686,769
Avg Volume360,855
Beta0.56
Dividend—
Analyst Ratings
Company Info
CEOMary T. Szela
Employees110
SectorHealthcare
IndustryMedical - Devices
IPO Date2021-02-08
Websitetrisaluslifesci.com
6272 West 91st Avenue
Westminster, CO 80031
US
Westminster, CO 80031
US
888 321 5212
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
Latest News
TriSalus (TLSI) Q1 2026 Earnings Transcript
Nasdaq Surges Over 1%; Alibaba Shares Gain After Q4 Results
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
TriSalus outlines $54M-$57M 2026 revenue forecast while TriNav Advance clearance runs ~5 months past goal
TriSalus Life Sciences, Inc. Q1 2026 Earnings Call Summary
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Marshak Richard | S-Sale | 543 | $2.67 | 2026-05-15 |
| Wahlstrom Mats | P-Purchase | 60,000 | $2.53 | 2026-05-15 |
| Stansky Michael P | P-Purchase | 410,000 | $2.50 | 2026-05-15 |
| Stansky Michael P | P-Purchase | 200,000 | $2.50 | 2026-05-15 |
| Szela Mary T | P-Purchase | 39,682 | $2.59 | 2026-05-15 |